Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Παρασκευή 20 Σεπ 2019
Long term results of the phase III study were published. They confirm  our practice in  our Tx center Presenter: Prof. Spyridondis Particpants: Dr Liga, Dr Spyridis, Dr Verigou Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic  haemopoietic peripheral blood stem-cell transplantation from  HLA-identical siblings in patients with acute myeloid leukaemia...
Καταχωρήθηκε: Τρίτη 17 Σεπ 2019
Optimal conditioning for ALL. Does it exist?   Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Verigou
Καταχωρήθηκε: Τετάρτη 11 Σεπ 2019
Is an HLA-DRB1*1454/HLA-DRB1*1401 mismatchan acceptable mismatch in  hematopoietic stemcell transplantation? We discussed the role of such potential mismatches. We discussed the  G-coding and the imporance of typoing at exon 2 and 3 An abstract was presented Oudshoorn, Machteld & Lie, John & Roelen, Dave & Verduijn, Willem &  Claas, Frans....
Καταχωρήθηκε: Δευτέρα 02 Σεπ 2019
We discussed a phase II study on LEN/AZa or treatment relapse after  transplantation.   Presenter:Prof Spyridonidis Participants:Dr Liga,Dr Spyridis, Dr Fragopanagou, Dr Verigou
Καταχωρήθηκε: Πέμπτη 08 Αύγ 2019
We discussed a case of a young AML patient with  PTPN11 mutated (Glu76Lys, missense, NPM1 neg/ flt3 ITD neg) In a study (Hou et al, Leukemia volume 22, pages 1075–1078 (2008)  (https://doi.org/10.1182/blood-2018-99-110319) PTPN11 mutations were found in 5.1% adult AML patients and they were exclusively missense...
Καταχωρήθηκε: Τρίτη 02 Ιούλ 2019
According to bibliography, G-CSF administration on day -1, 8 or during febrile neutropenia is not relevant with the progression of the disease. In contrast, G-CSF administration reduces TRM and can accelerate ANC recovery. As a result, we decided to administer G-CSF from day 15 (from the...
Καταχωρήθηκε: Δευτέρα 10 Ιούν 2019
We presented a retospective analysis of BEAM vs BuCYVP16 in HL. BEAM conditioning before AHSCT resulted in a statistically significant  improved PFS and OS and lower relapse when compared with BUCYVP16.  Patients with shorter remission time from diagnosis and in non-CR at  time of AHSCT benefited most from...
Καταχωρήθηκε: Πέμπτη 23 Μάι 2019
When, Where, and How to use FLT3 inhibitors? What is their value? What are the open questions. Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Τρίτη 14 Μάι 2019
We discussed an excellent review on mechanisms of relapse and its  treatment. - Major mechanisms of relapse include HLA loss, HLA down-regulation, and  expression of coinhibitory ligands. - Combination of donor lymphocyte infusion with immunomodulating agents and tyrosine kinase inhibitors may enhance the graft-versus-leukemia (GVL) effect. - Immune checkpoint inhibitors can induce a...
Καταχωρήθηκε: Δευτέρα 06 Μάι 2019
Στα πλαίσια ενημέρωσης, την Τρίτη 9/4/2019 πραγματοποιήθηκε, στην αίθουσα σεμιναρίων της Παθολογικής κλινικής, παρουσίαση του φαρμακου Cresemba από εκπροσώπους της εταιρείας Pfizer.    
Καταχωρήθηκε: Δευτέρα 06 Μάι 2019
We discussed current concepts and treatment of HCV. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Παρασκευή 03 Μάι 2019
We discussed a case for BL/BLL which was referred for HSCT. We reviewed the literature regarding BL/ BLL/ DLBCL. In the 2008 revisions to the WHO classification, atypical BL/BLL is no longer formally recognized; many of these cases are now classified as BL, whereas others are...
Καταχωρήθηκε: Πέμπτη 18 Απρ 2019
We presented a case of an isolated myeloid sarcoma and discussed the  current literature with the specific question of transplant or not. Presenter:Prof Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Πέμπτη 11 Απρ 2019
Presenter:Prof Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Τρίτη 09 Απρ 2019
We discussed a case of conjuctival MALT lymphoma and reviewed the  current literature.   Presenter:Prof.Spyridonidis Participants:Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Πέμπτη 04 Απρ 2019
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Δευτέρα 01 Απρ 2019
Presenter:Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Πέμπτη 28 Μάρ 2019
We discussed 2 interesting papers for mechanisms of relapse post allogeneic HSCT which can be either HLA-loss, HLA-down regulation or immune escape. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Καταχωρήθηκε: Παρασκευή 15 Μάρ 2019
Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Katsaouni
Βρέθηκαν 191 αποτελέσματα. Σελίδα 1 από 10
Σελίδα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] >
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2019 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας